Analyzing the synthesis route of 201940-08-1

Some common heterocyclic compound, 201940-08-1, name is tert-Butyl 5-bromoisoindoline-2-carboxylate, molecular formula is C13H16BrNO2, traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route. HPLC of Formula: C13H16BrNO2

Some common heterocyclic compound, 201940-08-1, name is tert-Butyl 5-bromoisoindoline-2-carboxylate, molecular formula is C13H16BrNO2, traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc, below Introduce a new synthetic route. HPLC of Formula: C13H16BrNO2

To a 10OmL 3-neck round bottom flask are added 5-bromo-l,3-dihydro-isoindole-2- carboxylic acid tert-butyl ester (13.42 mmol; 1.0 equiv), Pd(OAc)2 (0.34 mmol; 0.025 equiv), and P(o-tol)3 (0.67 mmol; 0.05 equiv) and the flask is evacuated and purged with N2 three times. DMF (34 mL), methyl acrylate (14.76 mmol; 1.1 equiv), and Et3N (67.1 mmol; 5.0 equiv) are added and the reaction mixture is heated to 130 C for 15 h. The reaction is cooled to room temperature, diluted with Et2O (200 mL), and the organic layer is washed with 10% citric acid, saturated sodium hydrogen carbonate, and brine. The combined organic extracts are dried (MgSO4), filtered, and concentrated to afford the crude product, which is then purified by silica gel chromatography to yield 5-(2-methoxycarbonyl-vinyl)-l,3- dihydro-isoindole-2-carboxylic acid tert-butyl ester as a yellow solid (1.7 g; 42% yield). 1H NMR (400 MHz, CD3OD): delta 7.68 (d, J= 16 Hz, 1 H), 7.53 (m, 2 H), 7.32 (t, J= 8.0 Hz, 1 H), 6.52 (d, J= 16 Hz, 1 H), 4.64 (d, J= 8 Hz, 4 H), 3.78 (s, 3 H), 1.52 (s, 9 H). MS m/z 305.0 (M+l)+

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route 201940-08-1, its application will become more common.

Reference:
Patent; NOVARTIS AG; WO2008/76954; (2008); A2;,
Indoline – Wikipedia,
Indoline | C8H9N – PubChem